Artivion, Inc. (AORT) shareholders
Close on Nov 17, 2026Market cap $890.78MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 7,159,279 | 14.70% | 13G (passive) amendment | Sep 30, 2026 |
| Nomura Asset Management International Inc. Joint filing with Nomura Investment Management Business Trust (6.50%) | 3,184,974 | 6.50% | 13G (passive) amendment | Jun 30, 2026 |
| Nomura Investment Management Business Trust Joint filing with Nomura Asset Management International Inc. (5.50%) | 2,613,471 | 5.50% | 13G (passive) | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AORT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6,674,017 | 13.69% | $149.97M | +199,163 | 0.00% |
| Nomura Asset Management International Inc. | 3,184,974 | 6.53% | $71.57M | +728,828 | 0.11% |
| Morgan Stanley | 2,557,961 | 5.25% | $57.48M | +288,667 | 0.00% |
| Juniper Investment Company, LLC | 2,019,885 | 4.14% | $45.39M | +830,749 | 12.02% |
| Vanguard Capital Management LLC | 2,004,619 | 4.11% | $45.04M | +52,611 | 0.00% |
| FMR LLC | 1,963,471 | 4.03% | $44.12M | −619,956 | 0.00% |
| State Street Corp | 1,858,051 | 3.81% | $41.75M | +175,778 | 0.00% |
| Ophir Asset Management Pty Ltd | 1,800,008 | 3.69% | $40.45M | +849,158 | 3.33% |
| Perceptive Advisors LLC | 1,737,290 | 3.56% | $39.04M | +100,000 | 0.59% |
| Conestoga Capital Advisors, LLC | 1,623,700 | 3.33% | $36.48M | +448,290 | 0.79% |
| Wellington Management Group Llp | 1,260,279 | 2.58% | $28.32M | +103,592 | 0.00% |
| Geode Capital Management, LLC | 1,114,297 | 2.29% | $25.04M | −18,206 | 0.00% |
| Silvercrest Asset Management Group LLC | 1,024,091 | 2.10% | $23.01M | +363,150 | 0.15% |
| Vanguard Portfolio Management LLC | 988,219 | 2.03% | $22.21M | −49,226 | 0.00% |
| Dimensional Fund Advisors LP | 947,941 | 1.94% | $21.30M | −79,634 | 0.00% |
| Citadel Advisors LLC | 827,594 | 1.70% | $18.60M | +756,725 | 0.00% |
| GW&K Investment Management, LLC | 794,478 | 1.63% | $17.85M | +55,775 | 0.14% |
| First Eagle Investment Management, LLC | 693,146 | 1.42% | $15.57M | +381,545 | 0.01% |
| Royce & Associates LP | 639,282 | 1.31% | $14.36M | +214,000 | 0.12% |
| Yarger Wealth Strategies, LLC | 634,223 | 1.30% | $15.28M | – | 5.49% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 206 | 46M | 94.9% | 37 / 84 | 58 / 66 | 9M | 7M |
| Q1 2026 | 239 | 44M | 91.1% | 37 / 95 | 66 / 38 | 9M | 4M |
| Q4 2025 | 243 | 43M | 88.5% | 40 / 89 | 79 / 15 | 7M | 6M |
| Q3 2025 | 219 | 42M | 87.1% | 48 / 76 | 63 / 16 | 5M | 4M |
| Q2 2025 | 188 | 42M | 85.7% | 29 / 71 | 57 / 24 | 4M | 3M |
| Q1 2025 | 184 | 41M | 84.3% | 33 / 55 | 58 / 21 | 5M | 2M |
| Q4 2024 | 174 | 38M | 78.3% | 23 / 55 | 59 / 23 | 3M | 1M |
| Q3 2024 | 174 | 36M | 74.3% | 29 / 63 | 48 / 17 | 9M | 2M |
| Q2 2024 | 163 | 36M | 72.9% | 32 / 47 | 56 / 19 | 2M | 6M |
| Q1 2024 | 151 | 40M | 81.7% | 25 / 40 | 52 / 15 | 5M | 2M |
| Q4 2023 | 141 | 37M | 74.9% | 14 / 43 | 54 / 15 | 4M | 1M |
| Q3 2023 | 142 | 34M | 69.8% | 20 / 39 | 51 / 4 | 1M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
234 funds held AORT in Q2 2026, 48% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of AORT | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 2,574,183 | 5.28% | $57.84M | 0.05% | Jun 30, 2026 |
| Nomura Small Cap Core Fund | 1,737,106 | 3.56% | $38.55M | 0.70% | May 29, 2026 |
| Vanguard Total Stock Market Index Fund | 1,463,340 | 3.00% | $32.88M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,186,684 | 2.43% | $26.66M | 0.03% | Jun 30, 2026 |
| Conestoga Small Cap Fund | 962,620 | 1.97% | $21.63M | 1.06% | Jun 30, 2026 |
| Fidelity Small Cap Value Fund | 610,573 | 1.25% | $16.38M | 0.30% | Jul 31, 2026 |
| Nomura Small Cap Growth Fund | 547,605 | 1.12% | $12.30M | 1.05% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 532,577 | 1.09% | $14.29M | 0.16% | Jul 31, 2026 |
| Fidelity Stock Selector Small Cap Fund | 510,613 | 1.05% | $13.70M | 0.19% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 498,998 | 1.02% | $13.39M | 0.04% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 495,440 | 1.02% | $11.13M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 429,440 | 0.88% | $9.65M | 0.06% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 390,508 | 0.80% | $8.77M | 0.05% | Jun 30, 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 382,739 | 0.79% | $8.60M | 0.10% | Jun 30, 2026 |
| First Eagle Small Cap Opportunity Fund | 322,550 | 0.66% | $8.65M | 0.30% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Andrew M. Green | SVP, Regulatory and Quality | 40,160 | 0.08% | Sep 11, 2026 |
| James P. Mackin | President & CEO | 877,275 | 1.80% | Aug 20, 2026 |
| Lance A. Berry | EVP, COO, CFO & Treasurer | 210,112 | 0.43% | Aug 17, 2026 |
| Jean F. Holloway | SVP, General Counsel | 184,118 | 0.38% | Aug 12, 2026 |
| Amy Horton | VP, Chief Accounting Officer | 139,088 | 0.29% | Mar 4, 2026 |
| John E. Davis | Chief Commercial Officer | 230,794 | 0.47% | Mar 4, 2026 |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 60,097 | 0.12% | Mar 4, 2026 |
| Anthony B. Semedo | Director | 47,560 | 0.10% | Jun 4, 2026 |
| James Bullock | Director | 76,223 | 0.16% | May 20, 2026 |
| Jeffrey H. Burbank | Director | 61,372 | 0.13% | May 20, 2026 |
| Marna P. Borgstrom | Director | 56,664 | 0.12% | May 20, 2026 |
| Elizabeth A. Hoff | Director | 34,765 | 0.07% | May 20, 2026 |
| Daniel J. Bevevino | Director | 157,637 | 0.32% | May 20, 2026 |
| Thomas F. Ackerman | Director | 157,472 | 0.32% | May 20, 2026 |
| Jon W. Salveson | Director | 137,416 | 0.28% | May 20, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Andrew M. Green SVP, Regulatory and Quality | Sep 10, 2026 | Sale | −11,480 | $24.97 | $286.66K | 40,160 |
| Andrew M. Green SVP, Regulatory and Quality | Sep 3, 2026 | Sale | −1,493 | $26.02 | $38.85K | 51,640 |
| Andrew M. Green SVP, Regulatory and Quality | Sep 2, 2026 | Sale | −6,510 | $27.27 | $177.53K | 53,133 |
| James P. Mackin President & CEO | Aug 19, 2026 | Sale | −70,000 | $28.96 | $2.03M | 877,275 |
| Andrew M. Green SVP, Regulatory and Quality | Aug 14, 2026 | Sale | −616 | $28.55 | $17.59K | 59,643 |
| Lance A. Berry EVP, COO, CFO & Treasurer | Aug 14, 2026 | Sale | −715 | $28.55 | $20.41K | 210,112 |
| Jean F. Holloway SVP, General Counsel | Aug 12, 2026 | Sale | −977 | $28.49 | $27.83K | 184,118 |
| Andrew M. Green SVP, Regulatory and Quality | Jun 11, 2026 | Option exercise | +30,000 | $11.03 | $330.90K | 90,259 |
| Andrew M. Green SVP, Regulatory and Quality | Jun 11, 2026 | Sale(10b5-1 plan) | −14,001 | $20.71 | $289.96K | 60,259 |
| Andrew M. Green SVP, Regulatory and Quality | Jun 11, 2026 | Option exercise | +14,001 | $18.44 | $258.18K | 74,260 |
| Andrew M. Green SVP, Regulatory and Quality | Jun 11, 2026 | Sale(10b5-1 plan) | −30,000 | $20.69 | $620.70K | 60,259 |
| Anthony B. Semedo Director | Jun 2, 2026 | Other | +6,325 | – | – | 6,325 |
| Anthony B. Semedo Director | Jun 2, 2026 | Other | −6,325 | – | – | 40,635 |
| Jeffrey H. Burbank Director | May 18, 2026 | Award | +7,576 | – | – | 61,372 |
| Daniel J. Bevevino Director | May 18, 2026 | Award | +7,576 | – | – | 157,637 |
| Thomas F. Ackerman Director | May 18, 2026 | Award | +7,576 | – | – | 157,472 |
| Jon W. Salveson Director | May 18, 2026 | Award | +7,576 | – | – | 137,416 |
| Marna P. Borgstrom Director | May 18, 2026 | Award | +7,576 | – | – | 56,664 |
| Elizabeth A. Hoff Director | May 18, 2026 | Award | +7,576 | – | – | 34,765 |
| James Bullock Director | May 18, 2026 | Award | +7,576 | – | – | 76,223 |
| Anthony B. Semedo Director | May 18, 2026 | Award | +7,576 | – | – | 46,960 |
| Marna P. Borgstrom Director | May 14, 2026 | Award | +7,850 | – | – | 56,938 |
| Jean F. Holloway SVP, General Counsel | Mar 4, 2026 | Sale | −8,962 | $38.00 | $340.56K | 185,095 |
| Marshall S. Stanton SVP, Clinical & MD Affair | Mar 3, 2026 | Sale | −2,149 | $37.78 | $81.19K | 60,097 |
| James P. Mackin President & CEO | Mar 3, 2026 | Sale | −17,887 | $37.78 | $675.77K | 947,275 |
| Lance A. Berry EVP, COO, CFO & Treasurer | Mar 3, 2026 | Sale | −6,316 | $37.78 | $238.62K | 210,827 |
| Jean F. Holloway SVP, General Counsel | Mar 3, 2026 | Sale | −3,843 | $37.78 | $145.19K | 194,057 |
| Amy Horton VP, Chief Accounting Officer | Mar 3, 2026 | Sale | −901 | $37.78 | $34.04K | 139,088 |
| John E. Davis Chief Commercial Officer | Mar 3, 2026 | Sale | −4,573 | $37.78 | $172.77K | 230,794 |
| Marshall S. Stanton SVP, Clinical & MD Affair | Mar 2, 2026 | Award | +21,838 | – | – | 62,246 |
| James P. Mackin President & CEO | Mar 2, 2026 | Award | +116,948 | – | – | 965,162 |
| Lance A. Berry EVP, COO, CFO & Treasurer | Mar 2, 2026 | Award | +40,874 | – | – | 217,143 |
| Jean F. Holloway SVP, General Counsel | Mar 2, 2026 | Award | +27,795 | – | – | 197,900 |
| Amy Horton VP, Chief Accounting Officer | Mar 2, 2026 | Award | +7,475 | – | – | 139,989 |
| John E. Davis Chief Commercial Officer | Mar 2, 2026 | Award | +28,845 | – | – | 235,367 |
| Marshall S. Stanton SVP, Clinical & MD Affair | Mar 2, 2026 | Sale | −1,513 | $38.02 | $57.52K | 40,408 |
| James P. Mackin President & CEO | Mar 2, 2026 | Sale | −14,911 | $38.02 | $566.92K | 848,214 |
| Lance A. Berry EVP, COO, CFO & Treasurer | Mar 2, 2026 | Sale | −5,178 | $38.02 | $196.87K | 176,269 |
| Amy Horton VP, Chief Accounting Officer | Mar 2, 2026 | Sale | −641 | $38.02 | $24.37K | 132,514 |
| John E. Davis Chief Commercial Officer | Mar 2, 2026 | Sale | −2,784 | $38.02 | $105.85K | 206,522 |
| Jean F. Holloway SVP, General Counsel | Mar 2, 2026 | Sale | −2,183 | $38.02 | $83.00K | 170,105 |
| Marshall S. Stanton SVP, Clinical & MD Affair | Feb 24, 2026 | Sale | −1,259 | $35.69 | $44.93K | 41,921 |
| John E. Davis Chief Commercial Officer | Feb 24, 2026 | Award | +20,438 | – | – | 209,306 |
| John E. Davis Chief Commercial Officer | Feb 24, 2026 | Sale | −2,075 | $35.69 | $74.06K | 188,868 |
| Amy Horton VP, Chief Accounting Officer | Feb 24, 2026 | Award | +5,658 | – | – | 133,155 |
| Amy Horton VP, Chief Accounting Officer | Feb 24, 2026 | Sale | −830 | $35.69 | $29.62K | 127,497 |
| Jean F. Holloway SVP, General Counsel | Feb 24, 2026 | Sale | −1,668 | $35.69 | $59.53K | 152,203 |
| Jean F. Holloway SVP, General Counsel | Feb 24, 2026 | Award | +20,085 | – | – | 172,288 |
| Lance A. Berry EVP, COO, CFO & Treasurer | Feb 24, 2026 | Award | +37,482 | – | – | 181,447 |
| Lance A. Berry EVP, COO, CFO & Treasurer | Feb 24, 2026 | Sale | −4,485 | $35.69 | $160.07K | 143,965 |
| James P. Mackin President & CEO | Feb 24, 2026 | Sale | −13,936 | $35.69 | $497.38K | 766,095 |
| James P. Mackin President & CEO | Feb 24, 2026 | Award | +97,030 | – | – | 863,125 |
| Marshall S. Stanton SVP, Clinical & MD Affair | Feb 23, 2026 | Sale | −2,423 | $37.59 | $91.08K | 43,180 |
| John E. Davis Chief Commercial Officer | Feb 23, 2026 | Sale | −3,773 | $37.59 | $141.83K | 190,943 |
| Amy Horton VP, Chief Accounting Officer | Feb 23, 2026 | Sale | −1,731 | $37.59 | $65.07K | 128,327 |
| Jean F. Holloway SVP, General Counsel | Feb 23, 2026 | Sale | −3,079 | $37.59 | $115.74K | 153,871 |
| Lance A. Berry EVP, COO, CFO & Treasurer | Feb 23, 2026 | Sale | −4,981 | $37.59 | $187.24K | 148,450 |
| James P. Mackin President & CEO | Feb 23, 2026 | Sale | −20,962 | $37.59 | $787.96K | 780,031 |
| Marshall S. Stanton SVP, Clinical & MD Affair | Dec 31, 2025 | Award | +316 | $26.14 | $8.26K | 45,603 |
| Jean F. Holloway SVP, General Counsel | Dec 31, 2025 | Award | +228 | $26.14 | $5.96K | 156,950 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Artivion's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,539 shares on Aug 28, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Andrew M. Green Officer | Sep 10, 2026 | 11,480 | $286.66K | Sep 10, 2026 | Restricted Stock Vesting |
| Andrew M. Green Officer | Sep 3, 2026 | 1,493 | $38.84K | Sep 3, 2026 | Restricted Stock Vesting |
| Andrew M. Green Officer | Sep 2, 2026 | 6,510 | $177.50K | Sep 2, 2026 | Restricted Stock Vesting |
| Marshall S. Stanton Officer | Aug 27, 2026 | 7,400 | $198.69K | Aug 27, 2026 | ESPP Purchase |
| James P. Mackin Officer | Aug 19, 2026 | 70,000 | $2.05M | Aug 19, 2026 | Payment for Services Rendered |
| Lance A. Berry Officer | Aug 14, 2026 | 715 | $20.41K | Aug 14, 2026 | Restricted Stock Vesting |
| Andrew M. Green Officer | Aug 14, 2026 | 616 | $17.59K | Aug 14, 2026 | Restricted Stock Vesting |
| Andrew M. Green Officer | Jun 11, 2026 | 44,001 | $910.75K | Jun 11, 2026 | Stock Option Exercise |
| Jean F. Holloway Officer | Mar 4, 2026 | 8,962 | $340.56K | Mar 4, 2026 | Performance Shares |
| Jean F. Holloway Officer | Mar 3, 2026 | 3,843 | $145.17K | Mar 3, 2026 | Restricted Stock Vesting |
| John E. Davis Officer | Mar 3, 2026 | 4,573 | $172.75K | Mar 3, 2026 | Restricted Stock Vesting |
| Lance A. Berry Officer | Mar 3, 2026 | 6,316 | $238.59K | Mar 3, 2026 | Restricted Stock Vesting |
| Marshall S. Stanton Officer | Mar 3, 2026 | 2,149 | $81.18K | Mar 3, 2026 | Restricted Stock Vesting |
| James P. Mackin Officer, Director | Mar 3, 2026 | 17,887 | $675.69K | Mar 3, 2026 | Restricted Stock Vesting |
| Amy Horton Officer | Mar 3, 2026 | 901 | $34.04K | Mar 3, 2026 | Restricted Stock Vesting |
Congress trades
13 trades in Artivion reported by 2 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Gilbert Cisneros CA31 | Bought | Aug 20, 2026 | $1K–15K | Sep 10, 2026 |
| Gilbert Cisneros CA31 | Bought | Jul 16, 2026 | $1K–15K | Sep 4, 2026 50 days late |
| Gilbert Cisneros CA31 | Sold (part) | Oct 9, 2025 | $1K–15K | Nov 18, 2025 |
| Josh Gottheimer NJ05 · joint account | Bought | Jul 14, 2023 | $1K–15K | Aug 21, 2023 |
| Josh Gottheimer NJ05 · joint account | Sold (part) | Jun 13, 2023 | $1K–15K | Jul 11, 2023 |
| Josh Gottheimer NJ05 · joint account | Bought | Oct 16, 2020 | $1K–15K | Nov 5, 2020 |
| Josh Gottheimer NJ05 · joint account | Sold | Sep 15, 2020 | $1K–15K | Oct 13, 2020 |
| Gilbert Cisneros CA31 | Bought | Aug 12, 2020 | $1K–15K | Sep 14, 2020 |
| Gilbert Cisneros CA31 | Bought | Jul 17, 2020 | $1K–15K | Aug 19, 2020 |
| Gilbert Cisneros CA31 | Bought | Jun 25, 2020 | $1K–15K | Jul 17, 2020 |
| Gilbert Cisneros CA31 | Bought | May 11, 2020 | $1K–15K | Jun 16, 2020 |
| Gilbert Cisneros CA31 | Bought | Jan 17, 2020 | $1K–15K | Feb 18, 2020 |
| Josh Gottheimer NJ05 · joint account | Bought | Jan 14, 2020 | $1K–15K | Feb 10, 2020 |
See a number that looks wrong?